NIV-NAVA Versus Nasal Continuous Positive Airway Pressure (nCPAP) or Non Synchronized NIPPV
NCT ID: NCT02860325
Last Updated: 2017-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
56 participants
INTERVENTIONAL
2016-08-01
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recently, a new modality of synchronization has been available for pediatric and neonatal use: the neurally adjusted ventilatory assist (NAVA), which uses the diaphragmatic electrical activity (Edi) as a signal to start the rise in pressure of the ventilator, and to adjust the tidal volume and the inspiratory time (cycling off) to the patient needs, breath by breath.
The aims of this study are to know whether NIV-NAVA compared to unsynchronized modalities (nCPAP/nIPPV), in infants born \< 32 weeks GA with respiratory distress syndrome or requiring prophylactic NIV (immaturity, apnoea) reduces systemic inflammation, measured by serum cytokines concentration, reduces the need for oxygen and respiratory support, and if it increases the probabilities of survival without bronchopulmonary dysplasia (BPD).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During assisted ventilation, the lack of synchrony between patient efforts and ventilator support increases patient discomfort, favouring "fighting" the machine, and increases the risk of air trapping and lung overdistension. Even in patients with non-invasive ventilation (NIV), uneasiness and respiratory distress would cause air hunger, developing intrapleural negative pressure with risk of lung overinflation despite using low airway positive pressures. The use of neuromuscular blockade in adults with acute respiratory distress syndrome (ARDS) has been associated with a decrease in serum cytokine levels and 90 days adjusted mortality.
NAVA uses the diaphragmatic electrical activity (Edi) as a signal to start the rise in pressure of the ventilator. Likewise, it allows automatic adjustment of peak inspiratory pressure (PIP) to the patient's effort, providing variable tidal volume according to his/her needs. Finally, the system allows the inspiratory cycling off with Edi decline (normally set at 70% of Edi Peak), that is, with diaphragmatic relaxation. NAVA has shown a faster response time and a better level of synchronization than traditional flow or pressure systems, achieving greater comfort levels in adults and paediatric patients. Some paediatric and neonatal studies have shown a reduction in PIP, without changes in mean airway pressure (MAP), and a reduction in oxygen requirement (FiO2). These changes were not associated with major complications (intraventricular haemorrhage, pneumothorax, or necrotizing enterocolitis).
A relevant target in neonatal ventilatory support is to minimize the aggression to the lungs and respiratory system using NIV whenever possible, and/or extubating patients as soon as possible. For this reason, profound sedation, analgesia, or neuromuscular blockade are rarely indicated in the newborn period. NAVA synchronization might improve patient comfort, preventing patient-ventilator fighting, and lung overinflation episodes (volutrauma), ultimately reducing biotrauma. To the knowledge of the investigators, studies evaluating this new ventilatory modality (NAVA) in the newborn period are still scarce, and its potential to reduce inflammation has not been tested.
Objectives.
To determine if NIV-NAVA compared to unsynchronized modalities (nCPAP/nIPPV), in infants born \< 32 weeks GA with respiratory distress syndrome or requiring prophylactic NIV (immaturity, apnoea):
1. Reduces systemic inflammation, measured by serum cytokines concentration.
2. Reduces the need for oxygen and respiratory support.
3. Increases the probabilities of survival without bronchopulmonary dysplasia (BPD).
Design. Single centre, prospective and controlled randomized clinical trial.
Setting. Tertiary Hospital with near 6000 births per year and a Neonatal Intensive Care Unit (NICU) with 15 beds and approximately 250 admissions per year.
Methods. Informed consent (IC) will be obtained before birth, during mothers' admission with threatened preterm labour. Once the IC is obtained and after the infant's birth, patients will be randomized by a random numbers table, kept in sealed envelops, to "Group A" (NAVA) or "Group B" (conventional strategies).
In all cases meeting inclusion criteria, a cord blood sample will be collected to determine the level of cytokines: Tumour necrosis factor alpha (TNF - α), interleukin (IL) 1 beta (IL-1ß), IL-6, and IL-8.
The decision to intubate in delivery room or to provide NIV will be carried out by the attending neonatologist at time of birth based on clinical criteria. In our unit, standard care is intubation and prophylactic surfactant administration in delivery room in neonates \< 25 weeks GA, or older babies that did not received antenatal steroid and need intubation during resuscitation. Neonates 26 - 29 weeks GA with adequate respiratory effort are resuscitated and transferred to NICU with NIV (Neo-puff ®). Preterm babies \> 29 weeks GA receive respiratory support (invasive or NIV) only when clinically indicated.
After admission to NICU, patients requiring invasive mechanical ventilation will be supported according to theirs needs and the criteria of the attending neonatologist. In our unit, modes with volume guarantee (VG) or volume control are currently used: Assist/Control+VG, Synchronized - Intermittent Mandatory Ventilation (S-IMV)+VG, and Pressure Regulated Volume Control (PRVC). After extubation and in patients supported non-invasively since the beginning, NIV will be provided according to randomization group:
Group A: With the ventilator SERVO-n (Maquet, Solna, Sweden), in NIV-NAVA mode. The ventilation parameters (PEEP, FiO2, NAVA level, etc.) will be established and adjusted by the attending clinician according to the patient's needs.
Group B: With the Infant Flow device (CareFusion) in nCPAP or non-synchronised Biphasic mode. The ventilation parameters (Flow, PEEP, FiO2, PIP level, etc.) will be established and adjusted by the attending clinician according to the patient's needs.
Surfactant (Curosurf ®, 100 mg/kg) will be administered according to clinical indications following the Unit's protocol. In general, if the patient did not receive it in delivery room, it is administered as soon as possible in the NICU when the patient needs FiO2 \>0.3. Intubated patients will receive surfactant through a double lumen tube, and those with NIV by a minimally invasive method, or by the Insure (intubate, surfactant, and extubated) method.
Quantitative cytokine determination will be carried out simultaneously in all samples by X-MAP technology using the Bioplex cytometer (Biorad) which allows the simultaneous measure of multiple analytes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NIV-NAVA
Patients allocated to non-invasive NAVA
NIV-NAVA
Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
Conventional
Patients allocated to nasal CPAP or non-synchronized nasal IPPV
Conventional
Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NIV-NAVA
Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
Conventional
Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Newborns \< 29 weeks of gestation (GA) with non-invasive mechanical ventilation at admission indicated as per protocol.
3. Previous parent or legal guardian authorization (informed consent).
Exclusion Criteria
2. Absence of informed consent.
3. Outborn patients.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Complejo Hospitalario Universitario Insular Materno Infantil
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fermín García-Muñoz Rodrigo
Head of Neonatal Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fermín García-Muñoz Rodrigo, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Head of Neonatal Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario Universitario Insular Materno Infantil
Las Palmas de Gran Canaria, Las Palmas, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tremblay LN, Slutsky AS. Ventilator-induced injury: from barotrauma to biotrauma. Proc Assoc Am Physicians. 1998 Nov-Dec;110(6):482-8.
Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013 Nov 28;369(22):2126-36. doi: 10.1056/NEJMra1208707. No abstract available.
Stein H, Firestone K, Rimensberger PC. Synchronized mechanical ventilation using electrical activity of the diaphragm in neonates. Clin Perinatol. 2012 Sep;39(3):525-42. doi: 10.1016/j.clp.2012.06.004.
Forel JM, Roch A, Marin V, Michelet P, Demory D, Blache JL, Perrin G, Gainnier M, Bongrand P, Papazian L. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006 Nov;34(11):2749-57. doi: 10.1097/01.CCM.0000239435.87433.0D.
Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guerin C, Prat G, Morange S, Roch A; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372.
de la Oliva P, Schuffelmann C, Gomez-Zamora A, Villar J, Kacmarek RM. Asynchrony, neural drive, ventilatory variability and COMFORT: NAVA versus pressure support in pediatric patients. A non-randomized cross-over trial. Intensive Care Med. 2012 May;38(5):838-46. doi: 10.1007/s00134-012-2535-y. Epub 2012 Apr 6.
Breatnach C, Conlon NP, Stack M, Healy M, O'Hare BP. A prospective crossover comparison of neurally adjusted ventilatory assist and pressure-support ventilation in a pediatric and neonatal intensive care unit population. Pediatr Crit Care Med. 2010 Jan;11(1):7-11. doi: 10.1097/PCC.0b013e3181b0630f.
Stein H, Howard D. Neurally adjusted ventilatory assist in neonates weighing <1500 grams: a retrospective analysis. J Pediatr. 2012 May;160(5):786-9.e1. doi: 10.1016/j.jpeds.2011.10.014. Epub 2011 Dec 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEIC-CHUIMI-2014/761
Identifier Type: -
Identifier Source: org_study_id